Skip to main content
Clinical Trials/CTRI/2019/09/021152
CTRI/2019/09/021152CompletedPhase 3

Randomized Controlled Trial to compare two different doses of Folinic acid (leucovorin) in Methotrexate Toxicity - FLIMT

PGIMER Chandigarh0 sites38 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 3
Status
Completed
Enrollment
38

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • 1 A patient prescribed weekly or the biweekly dose of tablet or parenteral Methotrexate (up to 50 mg per week) for rheumatic or dermatologic or gastrointestinal disease
  • 2 Patient having methotrexate hematologic Toxicity defined as EITHER WBC less than 2000 AND OR Platelet count less than 50000 per microlitre (with or without mucositis)
  • 3 Either inadvertent overdose OR renal dysfunction

Exclusion Criteria

  • 1 Patient not consenting for the study
  • 2 Patient being treated with High Dose Methotrexate regimen.
  • 3 Patient <12 years of age
  • 4 Patient already received more than one dose of folinic acid

Investigators

Similar Trials